Literature DB >> 27466181

Huntingtin N17 domain is a reactive oxygen species sensor regulating huntingtin phosphorylation and localization.

Laura F DiGiovanni1, Andrew J Mocle1, Jianrun Xia1, Ray Truant2.   

Abstract

The N17 domain of the huntingtin protein is post-translationally modified and is the master regulator of huntingtin intracellular localization. In Huntington's disease (HD), mutant huntingtin is hypo-phosphorylated at serines 13 and 16 within N17, and increasing N17 phosphorylation has been shown to be protective in HD mouse models. Thus, N17 phosphorylation is defined as a sub-target of huntingtin for potential therapeutic intervention. We have previously shown that cellular stress can affect huntingtin nuclear entry and phosphorylation. Here, we demonstrate that huntingtin localization can be specifically affected by reactive oxygen species (ROS) stress. We have located the sensor of this stress to the N17 domain, specifically to a highly conserved methionine at position 8. In vitro, we show by circular dichroism spectroscopy structural studies that the alpha-helical structure of N17 changes in response to redox conditions and show that the consequence of this change is enhanced N17 phosphorylation and nuclear targeting of endogenous huntingtin. Using N17 substitution point mutants, we demonstrate that N17 sulphoxidation enhances N17 dissociation from the endoplasmic reticulum (ER) membrane. This enhanced solubility makes N17 a better substrate for phosphorylation and subsequent nuclear retention. This ability of huntingtin to sense ROS levels at the ER, with phosphorylation and nuclear localization as a response, suggests that ROS stress due to aging could be a critical molecular trigger of huntingtin functions and dysfunctions in HD and may explain the age-onset nature of the disorder.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27466181      PMCID: PMC5291230          DOI: 10.1093/hmg/ddw234

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  39 in total

1.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

2.  Kinase inhibitors modulate huntingtin cell localization and toxicity.

Authors:  Randy Singh Atwal; Carly R Desmond; Nicholas Caron; Tamara Maiuri; Jianrun Xia; Simonetta Sipione; Ray Truant
Journal:  Nat Chem Biol       Date:  2011-05-29       Impact factor: 15.040

3.  Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis.

Authors:  R J Perrin; W S Woods; D F Clayton; J M George
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

4.  Post-aggregation oxidation of mutant huntingtin controls the interactions between aggregates.

Authors:  Yasushi Mitomi; Takao Nomura; Masaru Kurosawa; Nobuyuki Nukina; Yoshiaki Furukawa
Journal:  J Biol Chem       Date:  2012-08-13       Impact factor: 5.157

Review 5.  Methionine oxidation, alpha-synuclein and Parkinson's disease.

Authors:  Charles B Glaser; Ghiam Yamin; Vladimir N Uversky; Anthony L Fink
Journal:  Biochim Biophys Acta       Date:  2004-11-25

6.  The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis.

Authors:  Erica Rockabrand; Natalia Slepko; Antonello Pantalone; Vidya N Nukala; Aleksey Kazantsev; J Lawrence Marsh; Patrick G Sullivan; Joan S Steffan; Stefano L Sensi; Leslie Michels Thompson
Journal:  Hum Mol Genet       Date:  2006-11-29       Impact factor: 6.150

7.  Causes of death in patients with Huntington's disease and in unaffected first degree relatives.

Authors:  S A Sørensen; K Fenger
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

8.  Identification of Genetic Factors that Modify Clinical Onset of Huntington's Disease.

Authors: 
Journal:  Cell       Date:  2015-07-30       Impact factor: 41.582

9.  A huntingtin-mediated fast stress response halting endosomal trafficking is defective in Huntington's disease.

Authors:  Siddharth Nath; Lise N Munsie; Ray Truant
Journal:  Hum Mol Genet       Date:  2014-09-08       Impact factor: 6.150

10.  SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation.

Authors:  Jacqueline Gire O'Rourke; Jaclyn R Gareau; Joseph Ochaba; Wan Song; Tamás Raskó; David Reverter; John Lee; Alex Mas Monteys; Judit Pallos; Lisa Mee; Malini Vashishtha; Barbara L Apostol; Thomas Peter Nicholson; Katalin Illes; Ya-Zhen Zhu; Mary Dasso; Gillian P Bates; Marian Difiglia; Beverly Davidson; Erich E Wanker; J Lawrence Marsh; Christopher D Lima; Joan S Steffan; Leslie M Thompson
Journal:  Cell Rep       Date:  2013-07-18       Impact factor: 9.423

View more
  22 in total

Review 1.  Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities.

Authors:  Rachel J Harding; Yu-Feng Tong
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

2.  High-mobility group box 1 links sensing of reactive oxygen species by huntingtin to its nuclear entry.

Authors:  Susie Son; Laura E Bowie; Tamara Maiuri; Claudia L K Hung; Carly R Desmond; Jianrun Xia; Ray Truant
Journal:  J Biol Chem       Date:  2018-12-11       Impact factor: 5.157

Review 3.  Huntington's disease: the coming of age.

Authors:  Mritunjay Pandey; Usha Rajamma
Journal:  J Genet       Date:  2018-07       Impact factor: 1.166

Review 4.  Exploring the role of high-mobility group box 1 (HMGB1) protein in the pathogenesis of Huntington's disease.

Authors:  Efthalia Angelopoulou; Yam Nath Paudel; Christina Piperi
Journal:  J Mol Med (Berl)       Date:  2020-02-08       Impact factor: 4.599

5.  N6-Furfuryladenine is protective in Huntington's disease models by signaling huntingtin phosphorylation.

Authors:  Laura E Bowie; Tamara Maiuri; Melanie Alpaugh; Michelle Gabriel; Nicolas Arbez; Danny Galleguillos; Claudia L K Hung; Shreya Patel; Jianrun Xia; Nicholas T Hertz; Christopher A Ross; David W Litchfield; Simonetta Sipione; Ray Truant
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-09       Impact factor: 11.205

6.  Post-Translational Modifications (PTMs), Identified on Endogenous Huntingtin, Cluster within Proteolytic Domains between HEAT Repeats.

Authors:  Tamara Ratovitski; Robert N O'Meally; Mali Jiang; Raghothama Chaerkady; Ekaterine Chighladze; Jacqueline C Stewart; Xiaofang Wang; Nicolas Arbez; Elaine Roby; Athanasios Alexandris; Wenzhen Duan; Ravi Vijayvargia; Ihn Sik Seong; Daniel J Lavery; Robert N Cole; Christopher A Ross
Journal:  J Proteome Res       Date:  2017-07-03       Impact factor: 4.466

7.  Structure of Membrane-Bound Huntingtin Exon 1 Reveals Membrane Interaction and Aggregation Mechanisms.

Authors:  Meixin Tao; Nitin K Pandey; Ryan Barnes; Songi Han; Ralf Langen
Journal:  Structure       Date:  2019-08-26       Impact factor: 5.006

Review 8.  Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease.

Authors:  Adewale Adegbuyiro; Faezeh Sedighi; Albert W Pilkington; Sharon Groover; Justin Legleiter
Journal:  Biochemistry       Date:  2017-02-21       Impact factor: 3.162

Review 9.  PGC-1α, Sirtuins and PARPs in Huntington's Disease and Other Neurodegenerative Conditions: NAD+ to Rule Them All.

Authors:  Alejandro Lloret; M Flint Beal
Journal:  Neurochem Res       Date:  2019-05-07       Impact factor: 3.996

10.  Post-translational modifications clustering within proteolytic domains decrease mutant huntingtin toxicity.

Authors:  Nicolas Arbez; Tamara Ratovitski; Elaine Roby; Ekaterine Chighladze; Jacqueline C Stewart; Mark Ren; Xiaofang Wang; Daniel J Lavery; Christopher A Ross
Journal:  J Biol Chem       Date:  2017-09-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.